Nascent Biotech (NBIO) Stock Price & Analysis

NBIO Stock Chart & Stats

$0.00$0.00(0.00%)

At close: Oct 30 10:32 AM EDT

Day’s Range: $0.08 - $0.13
52-Week Range: $0.00 - $0.13
Previous Close: $0.08
Volume: N/A
Average Volume (3M): 74.01K
Market Cap: $34.57K
Enterprise Value: -$197.96B
Total Cash (Recent Filing): $47.39K
Total Debt (Recent Filing): $59.00K
Price to Earnings (P/E): ―
Beta: 61.94
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Nascent Biotech News

Nascent Biotech receives delinquency notification related to delayed filing

Nascent Biotech (NBIO) announced that it has received a written notification from the OTC Markets Group as a result of its failure to file its Quarterly Report on Form 10-Q

1y agoNBIO

Nascent Biotech Addresses OTC Filing Delinquency

Nascent Biotech ( ($NBIO) ) has issued an update. Nascent Biotech received a delinquency notice from the OTC for failing to file necessary disclosures on time. On January 16, 2025,

1y ago8K NBIO

Nascent Biotech recaps presentation at Emerging Growth Conference

Nascent Biotech is pleased to provide an overview of the Company’s presentation at The Emerging Growth Conference on July 18, 2024. NBIO CEO, Sean Carrick, and other Biotechnology Innovators, were

2y agoNBIO

Nascent Biotech embarks on fresh manufacturing run for pritumumab

Nascent Biotech is embarking on a fresh manufacturing run to ensure Pritumumab supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. This announcement

2y agoNBIO

Nascent Biotech collaborates with HypoSpray on transdermal delivery system

Nascent Biotech and HypoSpray Pharma announced a collaboration to develop an alternative delivery mechanism for patients who can benefit from Pritumumab, Nascent’s lead monoclonal antibody cancer treatment asset, which is

2y agoNBIO

Nascent Biotech, Manhattan BioSolutions partner to explore pritumumab conjugates

Nascent Biotech has entered into a research collaboration agreement with Manhattan BioSolutions to explore antibody-drug conjugates using Nascent’s lead clinical candidate pritumumab as the tumor-targeting antibody element. Pritumumab is a

2y agoNBIO

Nascent Biotech completes payment of variable convertible note

Nascent Biotech has completed payment of all outstanding variable convertible debt obligations. On August 30, 2023, the Company and the Noteholder YA II PN, LLC agreed to terms that fully

2y agoNBIO

Nascent Biotech granted Japanese patent for crossing blood-brain barrier

Nascent Biotech announced the Company has been issued a “Method-of-Use” patent from the Japanese Patent Office for its primary asset, Pritumumab. Specifically, the patent approval is related to PTB’s capacity

2y agoNBIO

Nascent Biotech to begin Phase II trials for brain cancer

Nascent Biotech has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical

3y agoNBIO

Nascent Biotech submits Phase 2 clinical research protocol to FDA

Nascent Biotech announced that the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval. The review is required for approval to commence the

3y agoNBIO

Nascent Biotech completes Phase 1 clinical trial for pritumumab

Nascent Biotech has completed and closed its Phase I clinical trial evaluating safety and tolerance for Pritumumab as a treatment for Primary and Metastatic Brain Cancers. Previous announcements shared the

3y agoNBIO

NBIO FAQ

What was Nascent Biotech’s price range in the past 12 months?

Nascent Biotech lowest stock price was $0.00 and its highest was $0.13 in the past 12 months.

What is Nascent Biotech’s market cap?

Nascent Biotech’s market cap is $34.57K.

When is Nascent Biotech’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Nascent Biotech overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Nascent Biotech pay dividends?

Nascent Biotech does not currently pay dividends.

What is Nascent Biotech’s EPS estimate?

Nascent Biotech’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nascent Biotech have?

Nascent Biotech has 172,842,670 shares outstanding.

Which hedge fund is a major shareholder of Nascent Biotech?

Currently, no hedge funds are holding shares in NBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nascent Biotech

Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma. This drug also targets numerous epithelial cancers, including those affecting the lung, breast, colon, brain, and pancreas. Additionally, the company is advancing MultiPharm, its proprietary technology platform, which holds promise for applications in cancer therapy, diabetes, autoimmune disorders, and transplantation. The company's headquarters are situated in Vero Beach, Florida.

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	9	5	2
Technical Analysis	3	5	2
Moving Averages	6	0	0

Technical Analysis >

Similar Stocks

Stocks similar to NBIO
Company	Price & Change	Follow
SCNIScinai Immunotherapeutics
GTBPGT Biopharma
ADTXAditxt
GRIGRI Bio
CEROCERo Therapeutics Holdings

Compare NBIO Stocks >

Ownership Overview

0.06% Other Institutional Investors
99.94% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

NBIO Stock Chart & Stats

Nascent Biotech News

Nascent Biotech receives delinquency notification related to delayed filing

Nascent Biotech Addresses OTC Filing Delinquency

Nascent Biotech recaps presentation at Emerging Growth Conference

Nascent Biotech embarks on fresh manufacturing run for pritumumab

Nascent Biotech collaborates with HypoSpray on transdermal delivery system

Nascent Biotech, Manhattan BioSolutions partner to explore pritumumab conjugates

Nascent Biotech completes payment of variable convertible note

Nascent Biotech granted Japanese patent for crossing blood-brain barrier

Nascent Biotech to begin Phase II trials for brain cancer

Nascent Biotech submits Phase 2 clinical research protocol to FDA

Nascent Biotech completes Phase 1 clinical trial for pritumumab

NBIO FAQ

Company Description

Nascent Biotech

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium